Lynparza
Payments companies reported to CMS as associated with Lynparza. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Lynparza, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Lynparza
These are the largest totals companies reported as associated with Lynparza. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Scott Sellinger | Tallahassee, FL | Urology | $274,526.50 |
| Sharyn Lewin | Teaneck, NJ | Gynecologic Oncology | $244,932.55 |
| John Chan | San Francisco, CA | Gynecologic Oncology | $232,382.50 |
| Thomas Krivak | Pittsburgh, PA | Gynecologic Oncology | $204,097.81 |
| Dan Veljovich | Seattle, WA | $127,567.29 | |
| Suresh Ratnam | Mcallen, TX | Medical Oncology | $107,902.71 |
| Nancy Dawson | Washington, DC | Medical Oncology | $93,196.46 |
| Mohammadbagher Ziari | Corona, CA | Hematology & Oncology | $92,724.17 |
| Dana Chase | Los Angeles, CA | Gynecologic Oncology | $91,976.56 |
| David Waterhouse | Cincinnati, OH | Hematology & Oncology | $91,471.02 |
Prescribed Lynparza?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.